Citigroup’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-50,000
Closed -$438K – 6120
2026
Q2
$438K Hold
50,000
– – ﹤0.01% 3967
2026
Q1
$384K Buy
+50,000
New +$342K ﹤0.01% 3695

Other funds holding IBRX

Citigroup's IBRX Position: Q3 2026 in Review

Citigroup reduced its ImmunityBio (IBRX) stake by 49% in Q3 2026, selling an estimated $2.16M and leaving 280,552 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2606.

Citigroup first reported a position in IBRX in Q3 2015 and has held it in 45 quarters since. The position peaked at $8.17M in Q1 2025. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Citigroup held 280,552 shares of ImmunityBio worth $2.65M as of Q3 2026.
  • Citigroup sold 269,724 ImmunityBio shares in Q3 2026, an estimated $2.16M.
  • ImmunityBio made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2606 holding.
  • Citigroup first reported a position in ImmunityBio in Q3 2015 and has held it in 45 quarters since.
  • Citigroup's ImmunityBio position peaked at $8.17M in Q1 2025.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.